| Basics |
Corbus Pharmaceuticals Holdings, Inc. Common Stock
Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
|
| IPO Date: |
November 1, 2014 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$78.93M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.31 | 3.91%
|
| Avg Daily Range (30 D): |
$0.32 | 4.87%
|
| Avg Daily Range (90 D): |
$0.34 | 4.25%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.31M |
| Avg Daily Volume (30 D): |
.13M |
| Avg Daily Volume (90 D): |
.18M |
| Trade Size |
| Avg Trade Size (Sh.): |
263 |
| Avg Trade Size (Sh.) (30 D): |
64 |
| Avg Trade Size (Sh.) (90 D): |
68 |
| Institutional Trades |
| Total Inst.Trades: |
430 |
| Avg Inst. Trade: |
$1.77M |
| Avg Inst. Trade (30 D): |
$.78M |
| Avg Inst. Trade (90 D): |
$.95M |
| Avg Inst. Trade Volume: |
.03M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.05M |
| Avg Closing Trade (30 D): |
$.78M |
| Avg Closing Trade (90 D): |
$.78M |
| Avg Closing Volume: |
39.83K |
|
|
|
|
| Financials |
| |
TTM |
Q4 2024 |
FY 2024 |
|
Basic EPS
|
$-1.39
|
$-.76
|
$-3.68
|
|
Diluted EPS
|
$-1.39
|
$-.76
|
$-3.68
|
|
Revenue
|
$ 1.68M
|
$ 3.55M
|
$ 6.31M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -16.98M
|
$ -9.53M
|
$ -40.21M
|
|
Operating Income / Loss
|
$ -19.78M
|
$ -12.61M
|
$ -48.72M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ M
|
$ -2.23M
|
$ 3.47M
|
|
PE Ratio
|
|
|
|
| Splits |
| Feb 14, 2023:
30:1
|
|
